Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRDF Cardiff Oncology, Inc.

Not Yet Opened 05-12 16:00:00 EDT

1.64

+0.01

+0.61%

盘后1.65

+0.01+0.61%

19:57 EDT

High1.67	Low1.61	Vol614.69K
Open1.64	D1 Closing1.63	Amplitude3.68%
Mkt Cap112.12M	Tradable Cap107.80M	Total Shares68.36M
T/O1.01M	T/O Rate0.94%	Tradable Shares65.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRDF","market":"US","secType":"STK","nameCN":"Cardiff Oncology, Inc.","latestPrice":1.64,"timestamp":1778616000000,"preClose":1.63,"halted":0,"volume":614685,"hourTrading":{"tag":"盘后","latestPrice":1.65,"preClose":1.64,"latestTime":"19:57 EDT","volume":559,"amount":919.5225,"timestamp":1778630239000,"change":0.01,"changeRate":0.006098,"amplitude":0.006098},"delay":0,"changeRate":0.0061349693251533804,"floatShares":65730400,"shares":68364979,"eps":-0.686345,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"05-12 16:00:00 EDT","open":1.64,"high":1.67,"low":1.61,"amount":1007286.153555,"amplitude":0.03681,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.686345,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778659200000},"marketStatusCode":0,"adr":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":1.63,"preHourTrading":{"tag":"盘前","latestPrice":1.63,"preClose":1.63,"latestTime":"09:21 EDT","volume":913,"amount":1505.7300082,"timestamp":1778592094914,"change":0,"changeRate":0,"amplitude":0.01227},"postHourTrading":{"tag":"盘后","latestPrice":1.65,"preClose":1.64,"latestTime":"19:57 EDT","volume":559,"amount":919.5225,"timestamp":1778630239000,"change":0.01,"changeRate":0.006098,"amplitude":0.006098},"volumeRatio":0.915563,"impliedVol":2.0451,"impliedVolPercentile":0.8287},"requestUrl":"/m/hq/s/CRDF/wiki","defaultTab":"wiki","newsList":[{"id":"2632693073","title":"Cardiff Oncology Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632693073","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632693073?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:40","pubTimestamp":1777894813,"startTime":"0","endTime":"0","summary":"Cardiff Oncology Inc  expected to post a loss of13cents a share - Earnings Preview Cardiff Oncology Inc CRDF.OQ CRDF.O is expected to  show a fall in quarterly revenue when it reports  results on May ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631534053","title":"Cardiff Oncology COO Ajay Aggarwal files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2631534053","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631534053?lang=en_us&edition=fundamental","pubTime":"2026-04-29 06:11","pubTimestamp":1777414317,"startTime":"0","endTime":"0","summary":"Cardiff Oncology named Ajay Aggarwal as chief operating officer in an initial Form 3 filing dated April 27, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL4yZM03:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631071538","title":"Cardiff Oncology grants COO inducement options for 400,000 shares at $1.72 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2631071538","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631071538?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:03","pubTimestamp":1777406596,"startTime":"0","endTime":"0","summary":"Cardiff Oncology granted Chief Operating Officer Aggarwal non-qualified stock options to buy 400,000 common shares.Option carried exercise price of $1.72 per share, set on April 27, 2026.Award vests over four years, starting with 25% after 12 months.Remaining shares vest monthly over following 36 months, subject to continued employment on vesting dates.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL50j1nq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014039.USD","NDAQ","LU2210149790.SGD","BK4588","BK4139","SG9999014013.SGD","IE00BN0W2W23.USD","LU2095319765.USD","CRDF","IE00B3QW5Z07.USD","BK4112","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631253820","title":"Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631253820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631253820?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:01","pubTimestamp":1777406460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUAZPYTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393884","title":"Cardiff Oncology to host KOL webinar on onvansertib single-agent CMML data","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393884","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393884?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:05","pubTimestamp":1777287929,"startTime":"0","endTime":"0","summary":"Cardiff Oncology will host a KOL webinar on onvansertib single-agent clinical activity in chronic myelomonocytic leukemia on April 30, 2026 at 11:00 a.m. ET.Mrinal Patnaik of Mayo Clinic will participate in discussion.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL7qMlcz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","CRDF","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","BK4588","BK4112","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629039865","title":"Cardiff Oncology announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629039865","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629039865?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:59","pubTimestamp":1776977991,"startTime":"0","endTime":"0","summary":"Cardiff Oncology schedules annual shareholder meeting in San Diego on June 11, 2026.Shareholders will vote to elect six directors to board.Meeting will also consider amending 2021 equity incentive plan to raise share authorization to 15,150,000 from 12,150,000.Advisory vote on named executive officer compensation is also slated.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLVzJPf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629451037","title":"Cardiff Oncology to present updated onvansertib Phase 2 mCRC data at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629451037","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629451037?lang=en_us&edition=fundamental","pubTime":"2026-04-21 22:01","pubTimestamp":1776780070,"startTime":"0","endTime":"0","summary":"Cardiff Oncology will present updated Phase 2 CRDF-004 data on onvansertib in first-line RAS-mutated metastatic colorectal cancer at ASCO Annual Meeting in Chicago on June 2, 2026.Rapid oral session scheduled for June 2, 2026, 8:00-9:30 AM CDT.ASCO 2026 meeting runs May 29-June 2, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL6lNdm7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","BK4139","CRDF","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628784842","title":"Cardiff Oncology to present preclinical data on onvansertib","url":"https://stock-news.laohu8.com/highlight/detail?id=2628784842","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628784842?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:14","pubTimestamp":1776456894,"startTime":"0","endTime":"0","summary":"Cardiff Oncology (CRDF) will present new preclinical data in a poster at the American Association for Cancer Research Annual Meeting, taking place ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-to-present-preclinical-data-on-onvansertib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cardiff-oncology-to-present-preclinical-data-on-onvansertib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628781902","title":"Cardiff Oncology reports preclinical onvansertib-T-DXd synergy in HER2-low breast cancer models","url":"https://stock-news.laohu8.com/highlight/detail?id=2628781902","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628781902?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:01","pubTimestamp":1776456088,"startTime":"0","endTime":"0","summary":"Cardiff Oncology announced new preclinical findings for onvansertib combined with trastuzumab deruxtecan  in HER2-low breast cancer models.Data were scheduled for presentation at AACR Annual Meeting 2026 on April 19, 2026.Results showed the combination improved antitumor activity and produced deeper responses than either agent alone in therapy-resistant settings.Study also indicated the regimen could overcome resistance to T-DXd in multiple breast cancer models.Cardiff reported favorable tolerability in animal testing, supporting potential further development of the combination.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL5t0XSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4588","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","BK4139","SG9999014021.USD","CRDF","LU0314104364.USD","BK4585","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628401612","title":"Cardiff Oncology CFO Joshua Muntner files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2628401612","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628401612?lang=en_us&edition=fundamental","pubTime":"2026-04-17 08:08","pubTimestamp":1776384530,"startTime":"0","endTime":"0","summary":"Cardiff Oncology CFO Joshua Muntner filed an initial Form 3 showing direct ownership of 500 common shares as of April 6, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL38zyNx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626153024","title":"BRIEF-Cardiff Oncology Announces Key Leadership Appointments To Strengthen Executive Team For Next Phase Of Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2626153024","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626153024?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:01","pubTimestamp":1775772108,"startTime":"0","endTime":"0","summary":"BRIEF-Cardiff Oncology Announces Key Leadership Appointments To Strengthen Executive Team For Next Phase Of GrowthApril 9 (Reuters) - Cardiff Oncology Inc CRDF.O:CARDIFF ONCOLOGY ANNOUNCES KEY LEADERS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA3NHRTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626130851","title":"Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2626130851","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626130851?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764897,"startTime":"0","endTime":"0","summary":"Cardiff Oncology named board member Mani Mohindru as president and CEO, following her stint as interim CEO.Josh Muntner was appointed CFO effective April 6; he previously served as CFO of Imvax and Mesoblast.Ajay Aggarwal was named COO effective April 27; he most recently served as SVP and head of clinical development at Aclaris Therapeutics.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL6mHz76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","BK7501","SG9999014021.USD","IE00BN0W2V16.EUR","MSB.AU","ACRS","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","BK4139","IE00B64PRP62.GBP","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","CRDF","LU2095319765.USD","IE00BGHQF748.EUR","BK4007","SG9999014013.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626137020","title":"Cardiff Oncology Inc - Appoints Josh Muntner as CFO Effective April 6 and Ajay Aggarwal as COO Effective April 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2626137020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626137020?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA3NHRTC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626078137","title":"Cardiff Oncology Inc - Appoints Mani Mohindru as President and CEO; to Continue as Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2626078137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626078137?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA3NHRTC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624825706","title":"Cardiff Oncology CEO Mark Erlander resigns as director after stepping down as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2624825706","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624825706?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:18","pubTimestamp":1775161097,"startTime":"0","endTime":"0","summary":"Cardiff Oncology entered separation agreements dated March 27, 2026 with former CEO Mark Erlander and former CFO James Levine.Agreements follow their departures disclosed Jan. 26, 2026, tied to a strategic review.Erlander also signed a consulting agreement with Cardiff Oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL8RZN5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387604","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387604?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:04","pubTimestamp":1774717440,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDYN","CV","BK4182","BK4606","ATLN","BK4008","RXT","GETY","BK4603","BK4139","BK4082","NFE","NNEX","CD","BK4023","BK4116","EVCM","SLS","BK4161","BK4604","BK4548","BYND","BK4077","BK4138","HURA","BK4608","SERV","CRDF","BK4212","BK4144","NNE","LCID","FLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826019","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826019?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:05","pubTimestamp":1774613100,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4116","BK4604","GETY","BK4144","BK4606","BK4548","EVCM","NNE","NFE","BK4182","BK4008","BK4603","BK4212","BYND","BK4138","PDYN","BK4023","CD","RXT","SLS","BK4139","CRDF","CV","BK4082","FLYX","ATLN","BK4608","HURA","NNEX","LCID","BK4077","BK4161","SERV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622770860","title":"Noble Financial Sticks to Its Buy Rating for Cardiff Oncology (CRDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622770860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622770860?lang=en_us&edition=fundamental","pubTime":"2026-03-27 01:25","pubTimestamp":1774545912,"startTime":"0","endTime":"0","summary":"In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cardiff Oncology, with a price target of $12.00. LeBoyer...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-its-buy-rating-for-cardiff-oncology-crdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/noble-financial-sticks-to-its-buy-rating-for-cardiff-oncology-crdf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRDF","NBL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622377448","title":"Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), CSPC Pharmaceutical Group (CHJTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622377448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622377448?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:30","pubTimestamp":1774513804,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiff Oncology (CRDF) and CSPC Pharmaceutical Grou...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-cardiff-oncology-crdf-cspc-pharmaceutical-group-chjtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-cardiff-oncology-crdf-cspc-pharmaceutical-group-chjtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BLSX","LU0128526141.USD","CHJTF","XBI","CRDF","BK4585","BK4112","BLSG","BK4581","BK4139","BK4007","LABU","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620806537","title":"Cardiff Oncology to host KOL webinar on first-line RAS-mutated metastatic colorectal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620806537","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620806537?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:01","pubTimestamp":1774004482,"startTime":"0","endTime":"0","summary":"Cardiff Oncology will host a key opinion leader webinar on March 25, 2026 at 4:30 p.m. ET focused on first-line RAS-mutated metastatic colorectal cancer.The discussion is scheduled to include Scott Kopetz and Heinz-Josef Lenz, along with interim CEO Mani Mohindru.The release includes an Events link for registration and webcast access.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8XlRsS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiffoncology.com","stockEarnings":[{"period":"1week","weight":0.0186},{"period":"1month","weight":0.038},{"period":"3month","weight":0.025},{"period":"6month","weight":-0.2372},{"period":"1year","weight":-0.4036},{"period":"ytd","weight":-0.4164}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0864},{"period":"3month","weight":0.0668},{"period":"6month","weight":0.0984},{"period":"1year","weight":0.2662},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.023989},{"month":2,"riseRate":0.5,"avgChangeRate":0.28397},{"month":3,"riseRate":0.357143,"avgChangeRate":0.075052},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.062128},{"month":5,"riseRate":0.428571,"avgChangeRate":0.044794},{"month":6,"riseRate":0.384615,"avgChangeRate":0.287657},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.07931},{"month":8,"riseRate":0.571429,"avgChangeRate":0.100833},{"month":9,"riseRate":0.285714,"avgChangeRate":0.016213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014863},{"month":11,"riseRate":0.357143,"avgChangeRate":0.032453},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.01141}],"exchange":"NASDAQ","name":"Cardiff Oncology, Inc.","nameEN":"Cardiff Oncology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cardiff Oncology, Inc.,CRDF,Cardiff Oncology, Inc.股票,Cardiff Oncology, Inc.股票老虎,Cardiff Oncology, Inc.股票老虎国际,Cardiff Oncology, Inc.行情,Cardiff Oncology, Inc.股票行情,Cardiff Oncology, Inc.股价,Cardiff Oncology, Inc.股市,Cardiff Oncology, Inc.股票价格,Cardiff Oncology, Inc.股票交易,Cardiff Oncology, Inc.股票购买,Cardiff Oncology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiff Oncology, Inc.(CRDF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cardiff Oncology, Inc.(CRDF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction